One pill, two problems: daily drug trial aims to halt silent organ damage
NCT ID NCT07391267
Summary
This study is testing whether a daily pill called oral semaglutide can slow down or prevent worsening kidney disease in people who also have fatty liver disease (MAFLD). It will involve 90 adults with both conditions, who will be randomly assigned to receive either the pill plus standard care or standard care alone for two years. The goal is to see if this single treatment can protect both organs by targeting shared underlying issues like inflammation and metabolic problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, 110070, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.